Chengdu Nuo´en Genomics Co., Ltd. announced that it has raised tens of millions of yuan in a round of funding led by new investor, Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), on January 14, 2024. The transaction included participation from new investor, Tibet Rhodiola Pharmaceutical Holding Co..
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
47.35 CNY | +0.62% | +2.31% | -2.97% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-2.97% | 1.62B | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- 600211 Stock
- News Tibet Rhodiola Pharmaceutical Holding Co.
- Chengdu Nuo´en Genomics Co., Ltd. announced that it has received funding from Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), Tibet Rhodiola Pharmaceutical Holding Co.